Cereno Scientific announced that an abstract regarding the innovative design of the Phase II study with drug candidate CS1 in pulmonary arterial hypertension (PAH) has been accepted as a poster presentation at the 15th Annual World Congress on Pulmonary Vascular Disease in Athens, Greece, on June 22-26, 2022. The abstract is a collaboration between Cereno, Dr. Raymond Benza, global PAH key opinion leader and principal investigator (PI) for the Phase II study and study collaborator Abbott. The congress organizer is the Pulmonary Vascular Research Institute (PVRI), a charity that brings together the best medical professionals in the world who have an interest in pulmonary hypertension or pulmonary vascular disease.

PVRI facilitates global research and development of medicines for the treatment of pulmonary hypertension and other pulmonary vascular diseases. Attendees at the PVRI World Congress includes medical professionals, drug regulatory bodies and professionals from the pharmaceutical industry. The abstract will be published in conjunction with the start of the congress on June 22, 2022.

Drug candidate CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator. The candidate's pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties are all relevant for PAH, an incurable, progressive disease with a significant unmet need for therapies that treat the underlying pathophysiology with improved safety, tolerability and efficacy profiles. The aim of the ongoing Phase II study is to evaluate CS1's safety, tolerability, and exploratory efficacy in PAH.

The study is run in collaboration with global healthcare company Abbott who is providing the cutting-edge CardioMEMS HF System for continuous monitoring of patients' pulmonary pressure.